Biogen Inc. (BIIB) Stock: Price, Forecast & Analyst Target
Biogen Inc. (BIIB) — MoonshotScore 37/100 (Weak band), calculated Nov 18, 2026. Price $251.41 (+0.25%), as of the Nov 18, 2026 trading session; market cap $37.2B. Expected results Feb 5, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Biogen Inc. · BIIB · NASDAQ · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Biogen sells branded therapies for neurological and neurodegenerative diseases, led by its multiple sclerosis franchise and Spinraza for spinal muscular atrophy. It is less a broad drug manufacturer than a concentrated neuroscience business whose results depend on the durability of established products, partnered medicines and successful pipeline renewal. The defining question is whether diversification beyond mature multiple sclerosis therapies can strengthen earnings before pipeline spending and debt narrow the financial room for error.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Biogen (BIIB)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet and stalling growth — yet price is running hot, well ahead of those stalled fundamentals; treat the move with suspicion, not chase. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Shrinking; Momentum: Surging.
- EPS beat 7 of the last 8 reports
- expected results Feb 5, 2027
- Altman Z 3.15 · Piotroski F 4
Holding back: balance-sheet strain, soft growth
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 41 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 37 | Weak | |
| 37 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $251.41 | |
| Change on the day | +0.25% | |
| 52-week range | $160.36–$261.00 | |
| Market capitalisation | $37.2B | — |
| Price / earnings (trailing) | 106.27 | |
| Shares traded on the day | 1.14M | |
| Beta (volatility vs the S&P 500) | 0.17 |
Why Biogen scores 37
Share price, last 12 months +53.8%
$164.73 $253.40
What the price assumes
5.9% a year of free-cash-flow growth for ten years is what a $37.46B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $2.05B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 10 of the last 12 reports (2024–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 3.7% either way.
- -9.8%Feb ’24
- +4.8%Apr ’24
- -3.5%Aug ’24
- -5.2%Oct ’24
- -0.7%Feb ’25
- +2.0%May ’25
- +4.2%Jul ’25
- +4.3%Oct ’25
- +4.6%Feb ’26
- +3.2%Apr ’26
- +1.1%Jul ’26
- -1.2%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | -1.2% | +0.7% | |
| Beat | Beat | +1.1% | +0.5% | |
| Beat | Beat | +3.2% | +4.0% | |
| Beat | Beat | +4.6% | +6.0% | |
| Beat | Beat | +4.3% | +6.0% | |
| Beat | Beat | +4.2% | +0.9% | |
| Beat | Beat | +2.0% | -2.2% | |
| In line | Beat | -0.7% | -1.7% | |
| Beat | Beat | -5.2% | -4.9% | |
| Beat | Miss | -3.5% | -4.3% | |
| Beat | In line | +4.8% | +11.9% | |
| Miss | Miss | -9.8% | -9.7% |
Beats have usually been rewarded — 7 of 10 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “high dose”, “appellis acquisition”, “spinraza high”, “another strong” — none of them came up in Q2 FY2026.
- Getting louder: “core pharmaceutical” (2 → 4 mentions), “inventory dynamics” (1 → 4 mentions).
- Gone quiet: “apellis transaction”, “biib dirinersen”, “btk inhibitor”, “early-stage pipeline” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 3.1 to 0.8 per 1,000 words, and confident words such as “record” and “strong” fell from 4 to 3.1.
Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.
Our track record on this stock
Since the score went from 64 to 37 while the share price moved +15.3% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Strong → Weak | — | — | — | |
| Fair → Strong | — | — | — | |
| Strong → Fair | — | — | — | |
| Fair → Strong | — | — | — | |
| Strong → Fair | — | — | — | |
| Fair → Strong | — | — | — |
None of the 10 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 67% of 49 rate it a buy; the average target sits +4.1% from the price of $251.41.
- Last 90 days: 2 upgrades and 0 downgrades among 23 rating actions.
- Our signals: Weak band; strongest pillar Momentum (92), weakest Growth Durability (15).
The crowd is more enthusiastic than our signals. Our Growth Durability reading is the main reason.
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Biogen (BIIB): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Biogen (BIIB), and what does it report?
Short answer · as of
Biogen discovers, develops and commercializes medicines, while also participating in biosimilars and collaboration arrangements.
Research dated 2026-09-12 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Demand is measured through sales of named therapies rather than patient services or research contracts, so product use, competitive persistence and partner execution drive the commercial result.
The disclosed revenue mix remains centered on multiple sclerosis products. Tysabri, fumarates and interferons are separately visible within that franchise, while Spinraza contributes exposure to spinal muscular atrophy; this concentration is more informative than the broad drug-manufacturer classification.
What do the latest results show for Biogen (BIIB)?
Research dated 2026-09-12 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
The latest period brought a revenue rebound and another result above the prevailing revenue and earnings estimates. The accounting outcome was less impressive: gross profit declined, selling and administrative expense rose, and operating income, net income and reported earnings per share all weakened despite higher sales.
Management says its core operating expense outlook incorporates investment across early-stage and late-stage pipeline programs. That identifies the spending priority, but it does not explain the revenue rebound; the reported statements show that improved sales have not yet translated into consistent operating leverage.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $2.80B | -$21M | -$0.14 (diluted) |
| Jun 2026 | $2.74B | $98M | $0.66 (diluted) |
| Mar 2026 | $2.48B | $320M | $2.15 (diluted) |
| Dec 2025 | $2.28B | -$49M | -$0.33 (diluted) |
What are the financial strengths and risks for Biogen (BIIB)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Operating cash flow remained positive throughout the reported series, with capital expenditure modest relative to cash generated. That supports continued research investment from the business itself, although annual net income declined even as revenue edged higher, and trailing profitability and returns remain restrained.
Debt substantially exceeds cash and investments. Cash and short-term investments also fell sharply in the latest period after previously building, leaving the closing balance below the opening level of the reported window. Near-term asset coverage remains adequate, but the net debt position makes durable cash conversion more important than headline liquidity alone.
The quality and distress screens are mixed rather than emphatic. Combined with uneven operating profit and earnings across recent periods, they argue for watching financial direction instead of treating any isolated result as representative.
What should you watch next at Biogen (BIIB)?
Short answer · as of
The next earnings report is expected on Feb 5, 2027. The number it tests is the $12.51 EPS analysts carry for it.
Research dated 2026-09-12 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
At the forthcoming earnings release, watch whether revenue holds near its recent rebound while gross profit and operating income recover. Biogen has repeatedly exceeded prevailing estimates, but the latest income statement shows that another revenue beat would not by itself establish better earnings quality.
Product disclosures should reveal whether Tysabri, fumarates and interferons still carry most of the mix, and whether Spinraza and the broader portfolio are reducing that dependence. Longer-range estimates assume gradual revenue and earnings expansion, so sustained diversification matters more than an isolated reporting surprise.
Cash flow, debt and the reduced cash balance deserve attention after recent acquisition activity and material agreements. Management has already incorporated pipeline investment into its expense outlook; the useful confirmation would be continued operating cash generation without further pressure on financial flexibility.
How does Biogen compare with its peers?
Short answer
Biogen's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered).
Biogen differs from more diversified drugmakers because its reported commercial base revolves around neuroscience franchises, especially multiple sclerosis. Spinraza adds a distinct neuromuscular business, while biosimilars, immunology products and collaboration arrangements broaden the model without changing its underlying concentration.
That structure makes the persistence of Tysabri, fumarates and interferons unusually visible in the revenue mix. Comparable businesses with broader therapeutic portfolios may spread product pressure across more franchises; Biogen instead relies more directly on neuroscience portfolio renewal and execution with named partners.
| Company | Price | Market value | Score |
|---|---|---|---|
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $82.52 Nov 18, 2026 | $30.8B | 93 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $59.56 Nov 18, 2026 | $122B | 85 5-pillar Nov 18, 2026 | |
| $178.76 Nov 18, 2026 | $277B | 85 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $155.21 Nov 18, 2026 | $293B | 82 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 | |
| $259.52 Nov 18, 2026 | $28.6B | 74 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $137.78 Nov 18, 2026 | $340B | 69 5-pillar Nov 18, 2026 | |
| Biogen (BIIB) — this page | $251.41 | $37.2B | 37 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $175.00 – $325.00
- Consensus target
- $261.83
- Median target
- $257.00
- Revenue estimate
- $10.60B
- EPS estimate
- $12.51
Consensus record · Captured .
Measured against a quoted price of $251.41 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 30, 2026
- Transactions
- 21
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 2
- Other transactions
- 19
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BIIB in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BIIB in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Biogen (BIIB)?
BIIB Healthcare Stock FAQ
Research dated 2026-09-12 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How dependent is Biogen on Tysabri and its multiple sclerosis portfolio?
Multiple sclerosis products remain the largest disclosed commercial grouping, with Tysabri, fumarates and interferons all contributing meaningful revenue. Their durability therefore has an outsized influence on whether growth elsewhere changes Biogen’s overall trajectory.
What role does Spinraza play in Biogen’s business mix?
Spinraza gives Biogen a substantial spinal muscular atrophy franchise outside its multiple sclerosis base. It diversifies the disease exposure, but the disclosed mix still leaves multiple sclerosis as the dominant grouping.
Why did Biogen’s latest revenue rebound not produce stronger profit?
The income statement shows lower gross profit, higher selling and administrative expense, and weaker operating and net income despite increased revenue. Research expense eased, so the broader cost and gross-profit pattern prevented the sales improvement from flowing through cleanly.
What should investors watch in Biogen’s pipeline spending plan?
Management says the operating expense outlook includes investment in early-stage and late-stage pipeline programs. The practical test is whether that spending remains compatible with positive operating cash flow while the cash balance is lower and debt remains substantial.
What is the BIIB stock price today?
The last price recorded for Biogen Inc. (BIIB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BIIB price target?
The analyst consensus price target for Biogen Inc. (BIIB), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold BIIB
Funds in our ETF coverage that list BIIB among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 4.36% | |
| The Free Markets ETF (FMKT) | 3.40% |
